Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week

Simply Wall St.12-19

It's been a soft week for Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares, which are down 12%. Despite this, the stock is a strong performer over the last year, no doubt about that. We're very pleased ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492172822?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","is_english":true,"pubTime":"2024-12-19 22:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492172822","market":"us","top_or_hot":-1,"title":"Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week","media":"Simply Wall St.","content":"<div>\n<p>It's been a soft week for Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares, which are down 12%. Despite this, the stock is a strong performer over the last year, no doubt about that. We're very pleased ...</p>\n\n<a href=\"https://finance.yahoo.com/news/investors-might-losing-patience-ocular-143156375.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/investors-might-losing-patience-ocular-143156375.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It's been a soft week for Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares, which are down 12%. Despite this, the stock is a strong performer over the last year, no doubt about that. We're very pleased ...</p>\n\n<a href=\"https://finance.yahoo.com/news/investors-might-losing-patience-ocular-143156375.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"USAW.SI","symbol_name":"AMZN 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/investors-might-losing-patience-ocular-143156375.html","article_id":"2492172822","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492172822","pubTimestamp":1734618716,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It's been a soft week for Ocular Therapeutix, Inc.  shares, which are down 12%. Despite this, the stock is a strong performer over the last year, no doubt about that. We're very pleased to report the share price shot up 115% in that time. So we think most shareholders won't be too upset about the recent fall. The real question is whether the business is trending in the right direction.Since the long term performance has been good but there's been a recent pullback of 12%, let's check if the fundamentals match the share price.Check out our latest analysis for Ocular Therapeutix. Over the last twelve months, Ocular Therapeutix's revenue grew by 6.5%. That's not a very high growth rate considering it doesn't make profits. So we wouldn't have expected the share price to rise by 115%. The business will need a lot more growth to justify that increase. We're not so sure that revenue growth is driving the market optimism about the stock.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"USAW.SI":"AMZN 3xLongSG261006","ISBC":"投资者银行","BK4007":"制药","BK4211":"区域性银行","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SQQQ":"纳指三倍做空ETF","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股",".IXIC":"NASDAQ Composite","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","USJW.SI":"ALPHAB 3xLongSG261006","QID":"纳指两倍做空ETF","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","TSYW.SI":"TESLA 3xLongSG261006","TQQQ":"纳指三倍做多ETF","NVIW.SI":"NVDA 3xLongSG261006","BK4112":"金融交易所和数据","PSQ":"纳指反向ETF","QLD":"纳指两倍做多ETF","OCUL":"Ocular Therapeutix","BK4585":"ETF&股票定投概念"},"translate_title":"投资者可能对Ocular Therapeutix（纳斯达克股票代码：OCUL）不断扩大的亏损失去耐心，该股在过去一周下跌了12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1,"NDAQ":1,"ISBC":1,".IXIC":1,"USJW.SI":0.6,"USAW.SI":0.6,"TSYW.SI":0.6,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NVIW.SI":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"It's been a soft week for Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares, which are down 12%. Despite this, the stock is a strong performer over the last year, no doubt about that. We're very pleased to report the share price shot up 115% in that time. So we think most shareholders won't be too upset about the recent fall. The real question is whether the business is trending in the right direction. \n Since the long term performance has been good but there's been a recent pullback of 12%, let's check if the fundamentals match the share price. \n Check out our latest analysis for Ocular Therapeutix \n Ocular Therapeutix wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. \n Over the last twelve months, Ocular Therapeutix's revenue grew by 6.5%. That's not a very high growth rate considering it doesn't make profits. So we wouldn't have expected the share price to rise by 115%. The business will need a lot more growth to justify that increase. We're not so sure that revenue growth is driving the market optimism about the stock. \n You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). \n\n\n\n  NasdaqGM:OCUL Earnings and Revenue Growth December 19th 2024\n \n\n You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic. \nA Different Perspective\n We're pleased to report that Ocular Therapeutix shareholders have received a total shareholder return of 115% over one year. That's better than the annualised return of 12% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted   3 warning signs for Ocular Therapeutix   you should know about. \n But note: Ocular Therapeutix may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). \nPlease note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492172822"}